Cargando…
Validating METCAM/MUC18 as a Novel Biomarker to Predict the Malignant Potential of Prostate Cancer at an Early Stage by Using a Modified Gold Nanoparticles-Based Lateral Flow Immunoassay
(1) Background: To further validate METCAM/MUC18 as a diagnostic biomarker for prostate cancer, a modified Lateral Flow Immune Assay (LFIA) with increased sensitivity and specificity was designed by taking advantage of the extremely high affinity between biotin and streptavidin and used. (2) Methods...
Autores principales: | Wu, Jui-Chuang, Chuang, Yin-Huan, Wei, Yu-Chun, Hsieh, Chia-Chi, Pong, Yuan-Hung, Su, Yenn-Rong, Tsai, Vincent F.-S., Wu, Guang-Jer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000444/ https://www.ncbi.nlm.nih.gov/pubmed/33806580 http://dx.doi.org/10.3390/diagnostics11030443 |
Ejemplares similares
-
METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells
por: Wu, Guang-Jer
Publicado: (2018) -
METCAM Is a Potential Biomarker for Predicting the Malignant Propensity of and as a Therapeutic Target for Prostate Cancer
por: Wu, Jui-Chuang, et al.
Publicado: (2023) -
Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells
por: Zeng, Guo-fang, et al.
Publicado: (2011) -
METCAM/MUC18 Plays a Tumor Suppressor Role in the Development of Nasopharyngeal Carcinoma Type I
por: Liu, Yen-Chun, et al.
Publicado: (2022) -
METCAM/MUC18 is a novel tumor and metastasis suppressor for the human ovarian cancer SKOV3 cells
por: Wu, Guang-Jer, et al.
Publicado: (2016)